Notice: This company has been marked as potentially delisted and may not be actively trading. Cerecor (CERC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends CERC vs. VRNA, RYTM, MLTX, JANX, XENE, EWTX, FOLD, MRUS, ACAD, and MORShould you be buying Cerecor stock or one of its competitors? The main competitors of Cerecor include Verona Pharma (VRNA), Rhythm Pharmaceuticals (RYTM), MoonLake Immunotherapeutics (MLTX), Janux Therapeutics (JANX), Xenon Pharmaceuticals (XENE), Edgewise Therapeutics (EWTX), Amicus Therapeutics (FOLD), Merus (MRUS), ACADIA Pharmaceuticals (ACAD), and MorphoSys (MOR). These companies are all part of the "medical" sector. Cerecor vs. Verona Pharma Rhythm Pharmaceuticals MoonLake Immunotherapeutics Janux Therapeutics Xenon Pharmaceuticals Edgewise Therapeutics Amicus Therapeutics Merus ACADIA Pharmaceuticals MorphoSys Verona Pharma (NASDAQ:VRNA) and Cerecor (NASDAQ:CERC) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation, dividends and community ranking. Which has more volatility & risk, VRNA or CERC? Verona Pharma has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Comparatively, Cerecor has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500. Which has better earnings and valuation, VRNA or CERC? Verona Pharma has higher earnings, but lower revenue than Cerecor. Verona Pharma is trading at a lower price-to-earnings ratio than Cerecor, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerona Pharma$5.62M601.01-$54.37M-$1.92-21.89Cerecor$6.70M127.68-$63.50M-$0.57-15.63 Is VRNA or CERC more profitable? Verona Pharma has a net margin of 0.00% compared to Cerecor's net margin of -1,194.82%. Verona Pharma's return on equity of -79.54% beat Cerecor's return on equity.Company Net Margins Return on Equity Return on Assets Verona PharmaN/A -79.54% -43.49% Cerecor -1,194.82%-261.82%-133.96% Do insiders & institutionals believe in VRNA or CERC? 85.9% of Verona Pharma shares are owned by institutional investors. Comparatively, 62.8% of Cerecor shares are owned by institutional investors. 4.8% of Verona Pharma shares are owned by insiders. Comparatively, 45.7% of Cerecor shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community believe in VRNA or CERC? Verona Pharma received 138 more outperform votes than Cerecor when rated by MarketBeat users. Likewise, 80.55% of users gave Verona Pharma an outperform vote while only 74.00% of users gave Cerecor an outperform vote. CompanyUnderperformOutperformVerona PharmaOutperform Votes32380.55% Underperform Votes7819.45%CerecorOutperform Votes18574.00% Underperform Votes6526.00% Do analysts recommend VRNA or CERC? Verona Pharma currently has a consensus target price of $43.83, indicating a potential upside of 4.32%. Given Verona Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Verona Pharma is more favorable than Cerecor.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verona Pharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Cerecor 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to VRNA or CERC? In the previous week, Verona Pharma had 3 more articles in the media than Cerecor. MarketBeat recorded 3 mentions for Verona Pharma and 0 mentions for Cerecor. Verona Pharma's average media sentiment score of 0.77 beat Cerecor's score of 0.16 indicating that Verona Pharma is being referred to more favorably in the media. Company Overall Sentiment Verona Pharma Positive Cerecor Neutral SummaryVerona Pharma beats Cerecor on 13 of the 18 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Cerecor News Delivered to You Automatically Sign up to receive the latest news and ratings for CERC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CERC vs. The Competition Export to ExcelMetricCerecorPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$855.44M$6.57B$5.13B$9.07BDividend YieldN/A2.99%5.08%4.23%P/E Ratio-15.6310.4289.5817.17Price / Sales127.68195.801,116.12116.95Price / CashN/A57.1642.8237.86Price / Book40.505.094.774.78Net Income-$63.50M$151.83M$120.15M$225.60M Cerecor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CERCCerecorN/A$8.91-1.9%N/A+21,016.3%$855.44M$6.70M-15.6331VRNAVerona Pharma0.7049 of 5 stars$42.79+3.3%$43.83+2.4%+153.4%$3.48B$460,000.00-22.2730Positive NewsRYTMRhythm Pharmaceuticals4.1121 of 5 stars$55.38+0.3%$63.70+15.0%+25.1%$3.40B$77.43M-12.76140Analyst ForecastNews CoveragePositive NewsMLTXMoonLake Immunotherapeutics1.6268 of 5 stars$52.98+3.2%$79.88+50.8%-9.3%$3.39BN/A-40.842JANXJanux Therapeutics3.6708 of 5 stars$61.79+1.1%$89.90+45.5%+496.3%$3.24B$13.05M-52.2330Positive NewsXENEXenon Pharmaceuticals2.7945 of 5 stars$41.30+3.1%$56.90+37.8%-5.8%$3.15B$9.43M-14.20251Insider TradeEWTXEdgewise Therapeutics2.722 of 5 stars$32.88+19.0%$42.33+28.8%+261.7%$3.11BN/A-22.8560Analyst ForecastAnalyst RevisionHigh Trading VolumeFOLDAmicus Therapeutics4.3254 of 5 stars$9.83+5.0%$16.88+71.7%-23.7%$2.94B$493.67M-28.71480Analyst DowngradeMRUSMerus2.8078 of 5 stars$42.90+0.2%$85.64+99.6%+61.7%$2.94B$35.93M-10.8437ACADACADIA Pharmaceuticals3.8468 of 5 stars$17.22-0.2%$25.60+48.7%-41.9%$2.87B$726.44M22.13510MORMorphoSys0.127 of 5 stars$18.96+2.4%$14.33-24.4%N/A$2.86B$238.28M-5.45730News Coverage Related Companies and Tools Related Companies Verona Pharma Alternatives Rhythm Pharmaceuticals Alternatives MoonLake Immunotherapeutics Alternatives Janux Therapeutics Alternatives Xenon Pharmaceuticals Alternatives Edgewise Therapeutics Alternatives Amicus Therapeutics Alternatives Merus Alternatives ACADIA Pharmaceuticals Alternatives MorphoSys Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CERC) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerecor Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cerecor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CERC Stock Alerts